Ginkgo Datapoints signs agreement with Lilly TuneLab
Ginkgo Bioworks (NYSE: DNA) says its Ginkgo Datapoints offering entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company.
Ginkgo Bioworks (NYSE: DNA) said its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab is designed to support biotech innovation by enabling participating companies to access the platform's AI/ML drug discovery capabilities.